Pipeline

Our clinical program for relugolix combination tablet* consists of three international Phase 3 clinical trials, two in women with endometriosis-associated pain (SPIRIT 1 & 2) and one in healthy women for the prevention of pregnancy (SERENE).

We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, as a potential trigger of egg maturation in women undergoing assisted reproduction, including in vitro fertilization (IVF).

*tablet is the intended commercial presentation based on pharmaco-equivalence data with relugolix combination therapy (co-administration of relugolix 40 mg with estradiol 1.0 mg and norethindrone acetate 0.5 mg)

Myovant Development

Relugolix Combination Tablet
Preclinical
Phase 1
Phase 2
Phase 3
NDA Submitted

Symptoms of Endometriosis

Combination Tablet:
relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg
Note:
Positive data from replicate Phase 3 studies reported in April and June 2020. Long-term extension data reported in January 2021. U.S. regulatory submission expected in the second quarter of 2021.

Prevention of Pregnancy

Combination Tablet:
relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg
MVT-602
Preclinical
Phase 1
Phase 2
Phase 3
NDA Submitted

Female Infertility as Part of Assisted Reproduction

Japanese Development

Learn more about our clinical trials

We cannot achieve our mission to redefine care for women and for men without clinical trials. All across the world, patients, families, physicians, and clinics support these trials as we strive to turn our purpose-driven science into empowering medicines.

View clinical trials